-
Cerliponase alfa,
marketed as
Brineura, is an
enzyme replacement treatment for
Batten disease, a
neurodegenerative lysosomal storage disease. Specifically...
- Food and Drug
Administration approved Brineura (cerliponase alfa) as the
first specific treatment for NCL.
Brineura is
enzyme replacement therapy manufactured...
-
involved in
glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as
Brineura), is an
enzyme replacement treatment for
Batten disease,
which is a form...
- illness; the FDA has
approved Brineura (cerliponase alfa) as a
treatment for a
specific form of
Batten disease.
Brineura is the
first FDA-approved treatment...
- Relenza, Climara, Proscar, Invega, Lunesta, Latisse, Entresto, Tremfya,
Brineura, Privigen, Zykadia, Tecfidera, Brukinsa, Zolgensma, Xpovio, and Qwo. Brand...
- 2017, the U.S. Food and Drug
Administration approved cerliponase alfa (
Brineura) as the
first specific treatment for NCL. It is
enzyme replacement therapy...
-
Emflaza Duchenne muscular dystrophy Marathon Pharmaceuticals Rare
pediatric Brineura Batten disease BioMarin Pharmaceutical Tropical disease benznidazole Chagas...
